Login

Vision Statement

Mission

To advance olfactory informational therapeutics by designing targeted interventions that use molecular information to support and communicate with endogenous physiological, cognitive, and emotional functions, enabling more precise, non-drug modulation of human readiness and symptom burden.


History

Aeroscena was founded in 2010 by CEO Mark Kohoot while he was acting as an advisor to Dr. Michael Roizen, Chief Wellness Officer at the Cleveland Clinic, where Aeroscena is now headquartered. At the time, aromatherapy’s reputation had been debased by false and exaggerated claims, adulterated products, and exploitative sales practices. Both saw the opportunity to rehabilitate the field by applying the same scientific rigor used in pharmaceuticals—rigorous quality standards, evidence-based claims, and clinical testing in major hospitals and healthcare institutions.

Since its founding, Aeroscena has established a higher standard of transparency, quality, and scientific rigor within aromatherapy and phyto-inhalants. Through collaborative partnerships with researchers and healthcare institutions, the company has supported clinical studies demonstrating positive outcomes related to pain, nausea, anxiety, and sleep. Today, Ascents® products are used in leading healthcare facilities across the United States, and the work has advanced toward olfactory informational therapeutics.

Company Milestones

Research & Clinical Collaborations

Maternal and Pediatric Health

  • Morning Sickness Associated with Pregnancy — Cleveland Clinic
  • Tantrum Mitigation in Children — University of California, Irvine

Palliative and Supportive Care

  • Mood, Nausea, and Pain Management — Children’s Hospital & Medical Center
  • Nausea and Anxiety Support — Moffitt Cancer Center
  • Virtual Reality Rehabilitation Therapy — Drexel University and Johns Hopkins University

Pain Management

  • Post-Knee Replacement Recovery Support — University of Washington

Anxiety Reduction

  • Anxiety Reduction During Venipuncture — Children’s National Hospital

Workplace Stress

  • Impact of Clinical Aromatherapy on ICU Nurse Stress Experience — University of California, Irvine

Recommended by Doctors. Used by Hospitals.®

Evidence-Informed Formulations

Aeroscena develops evidence-informed formulations as targeted olfactory interventions for state preparation. Each is designed to support readiness in specific domains—sleep, stress, focus, alertness, nausea, and discomfort—using molecular information to influence endogenous physiological, cognitive, and emotional functions.

Current formulations include:

  • Rest™
  • Calm™
  • Focus™
  • Energize™
  • Curb™
  • Nausea Relief™
  • Pain Management™

These are validated through clinical research and real-world use, with an expanding roadmap of additional olfactory interventions for healthcare, wellness, and hospitality.

Natural and Functional Fragrance

Aeroscena also develops natural and functional fragrance programs that extend the same design principles beyond clinical settings. These include custom signature scents, wellness-oriented ambient programs, and Fresh™, originally developed for the Delos Living Stay Well™ guest room program, prioritizing natural molecular inputs over synthetic fragrance systems.

Proprietary Delivery Systems

Delivery is integral to the intervention. Aeroscena’s technology platform is engineered for controlled timing, dose, and habituation management:

  • Precision personal inhalers designed using principles of fluid dynamics
  • Patented polymerized essential oil gel technology
  • Water-free, heat-free ambient diffusion systems
  • Proprietary diffuser timing algorithms that improve scent consistency and reduce habituation

Olfactory Informational Therapeutics

Aeroscena designs olfactory interventions using an integrative methodology that synthesizes olfactory neuroscience, predictive biology, allostasis, psychophysiology, behavioral ecology, and clinical scent research. The goal is targeted state preparation, using molecular information to support and communicate with endogenous functions rather than treating scent as mere atmosphere.

Attention to timing, dose, context, habituation, and defined endpoints is built into both formulation and delivery. As research advances, this approach supports more precise, non-drug modulation of human readiness and symptom burden.